Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00723775 · ClinicalTrials.gov registry record · Phase 1

GSK706769/KALETRA Drug-drug Interaction Study

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target

NCT00723775: Completed Phase 1 study, sponsored by GlaxoSmithKline.

NCT00723775 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00723775, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target

Study Summary

To compare plasma GSK706769 PK following repeat administration of GSK706769 QD with and without KALETRA (LPV 400 mg/RTV 100mg) q12h

Interventions

  • DRUG GSK706769 & KALETRA

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2008-07-24
Est. Completion 2008-11-08
Phase Phase 1
GlaxoSmithKline

1,345 total trials

What the finished NCT00723775 record still lists

NCT00723775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 1 intervention - of which GSK706769 & KALETRA is the first listed.

NCT00723775 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00723775 about?

NCT00723775 is a clinical study titled "GSK706769/KALETRA Drug-drug Interaction Study". To compare plasma GSK706769 PK following repeat administration of GSK706769 QD with and without KALETRA (LPV 400 mg/RTV 100mg) q12h

What is the current status of trial NCT00723775?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-07-24. Estimated completion is 2008-11-08.

What interventions are being tested in trial NCT00723775?

The interventions under investigation include: GSK706769 & KALETRA (DRUG).

Who is sponsoring clinical trial NCT00723775?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00723775's enrollment target sits among peer trials

17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00723775, the US trial registry maintained by the National Library of Medicine. NCT00723775 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.